PatientsVille.com Logo


Implanon Medical Research Studies

Up-to-date List of Implanon Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Implanon Medical Research Studies

Rank Status Study
1 Unknown  Is Cerazette Use Before Nexplanon Insertion Predictive for Bleeding Pattern?
Condition: Bleeding
Interventions: Drug: Desogestrel 75 micrograms POP (Cerazette), Etonogestrel 68 mg implant (Nexplanon);   Drug: Etonogestrel 68 mg subdermal implant
Outcome Measures: The total number of bleeding days per 90 days reference period in women using Cerazette before Nexplanon and in women starting Nexplanon without preceding POP;   The number of bleeding episodes according to WHO definitions
2 Not yet recruiting A Pharmacokinetic Evaluation of Etonogestrel (ENG) Implant and Antiretroviral Therapy
Conditions: HIV;   Contraception
Intervention: Drug: Etonogestrel
Outcome Measures: Etonogestrel plasma concentrations;   NNRTI plasma concentrations
3 Not yet recruiting Nexplanon Application Post-Abortion
Conditions: Contraception;   Abortion, Therapeutic
Interventions: Other: Immediate Nexplanon Insertion;   Other: Post-op Nexplanon Insertion
Outcome Measures: Nexplanon use;   Repeat pregnancy;   Side-effects of Nexplanon use;   Contraceptive method satisfaction
4 Recruiting Quantification of Immune Cells in Women Using Contraception (CHIC II)
Conditions: HIV;   Immune Cells (Mucosal and Systemic);   Contraception
Interventions: Drug: levonorgestrel exposure;   Drug: DMPA exposure;   Drug: etonogestrel exposure;   Device: IUD insertion;   Device: subdermal contraceptive implant insertion
Outcome Measures: Quantification and characterization of immune cell populations and HIV-tropic receptor expression;   Assessing changes in the vaginal microflora within the first 6 months of contraceptive use
5 Recruiting Does Concomitant Use of Combined Oral Hormonal Steroids Stop Bleeding in Women Using Etonogestrel Implants (Implanon/Nexplanon®)?: A Randomized Controlled Study
Conditions: Uterine Hemorrhage;   Contraception
Interventions: Drug: Combined Oral Contraceptive Pill;   Drug: Placebo Sugar Pill
Outcome Measures: Cessation of vaginal bleeding;   Length of cessation of vaginal bleeding
6 Unknown  New Treatments for Troublesome Bleeding in Implanon Users
Condition: Menstrual Problem
Intervention: Drug: Marvelon
Outcome Measures: The number of days to stop bleeding after initiation of each treatment group and placebo;   The mean total number of bleeding and spotting days during the 90 day "treatment" reference period
7 Recruiting Nexplanon Observational Risk Assessment Study (NORA)
Condition: Contraception
Outcome Measures: Insertion-, localization- and removal-related events;   Pregnancy and pregnancy outcomes;   Reasons for (premature) discontinuation of Nexplanon;   Baseline characteristics of Nexplanon users
8 Recruiting HIV-Target Cell Response in Women Initiating Various Contraceptive Methods in High HIV-Incidence Areas: Zim CHIC
Conditions: Contraception;   HIV;   Immune Cells (Mucosal and Systemic);   Microbiota
Interventions: Drug: DMPA;   Drug: NET-EN;   Drug: MPA/E2;   Device: LNG-I;   Device: ENG-I;   Device: Cu-IUD
Outcome Measures: Genital tract CD4 cells (number and % expressing CCR5);   Vaginal microbiota (key microbes);   Serum hemoglobin;   Serum concentration of estradiol and progesterone/progestin
9 Recruiting Quickstart of Nexplanon® at Medical Abortion
Conditions: Early Pregnancy Termination;   Medical Abortion;   Postabortion Contraception
Interventions: Drug: Mifepristone;   Drug: etonorgestrel
Outcome Measures: Complete abortions without surgical intervention;   Unplanned pregnancy;   Number of women with complications;   Rate of implant insertion;   Bleeding
10 Recruiting Management of Etonogestrel Subdermal Implant-related Bleeding
Condition: ESI-related Bleeding
Interventions: Drug: Doxycycline;   Drug: Placebo
Outcome Measures: Efficacy and safety of Doxycycline compared to placebo for unacceptable bleeding;   Patient Satisfaction;   Method Continuation rate
11 Recruiting Postpartum Etonogestrel Implant for Adolescents
Conditions: Adolescence;   Contraception;   Postpartum
Intervention: Drug: Contraceptive implant
Outcome Measures: Continuation at 1 year;   Satisfaction;   Rapid repeat pregnancy
12 Unknown  Effect of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring on Vaginal Innate and Inflammatory Biomarkers
Condition: Vaginosis, Bacterial
Intervention: Drug: Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring
Outcome Measures: Determine biomarkers of inflammation, including defensins and cytokines, concentrations in women with normal vaginal flora (Nugent Score 0 - 3) after 3 months of NuvaRing® use;   Determine changes in the integrity of cervicovaginal epithelium and leukocytic concentration after 3 months of treatment with NuvaRing®
13 Not yet recruiting Pharmacokinetics and Pharmacodynamics of the Etonogestrel Contraceptive Implant When Co-administered With Efavirenz
Condition: Drug Interaction
Intervention: Drug: Efavirenz
Outcome Measures: Serum concentration of etonogestrel before and after two weeks of efavirenz;   Serum efavirenz concentrations at the start and end of the 2-week dosing period;   Serum hormone markers of ovulation;   Transvaginal ultrasound to assess for ovarian follicular development;   Cervical mucus quality
14 Not yet recruiting Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
Condition: HIV-1 Infection
Interventions: Device: Etonogestrel/ethinyl estradiol vaginal ring (NuvaRing);   Drug: Efavirenz;   Drug: Atazanavir/Ritonavir
Outcome Measures: Etonogestrel and ethinyl estradiol concentrations at study day 21;   Etonogestrel and ethinyl estradiol concentrations obtained on study days 7 and 14 after vaginal ring administration in all three study arms;   Efavirenz (EFV) Pharmacokinetics (PK) area under curve (AUC)(0-24h), Cmin, Cmax, Tmax, and CL/F calculated based on intensive EFV PK samples obtained from individual participants enrolled in Arm B;   ATV and RTV PK AUC(0-24h), Cmin, Cmax, Tmax, and CL/F calculated based on intensive ATV and RTV PK samples obtained from individual participants enrolled in Arm C.;   HIV-1 RNA copies obtained from individual participants enrolled in all of the three study Arms A, B, and C;   Any signs and symptoms of grade 2 or higher related to vaginal ring exposure from individual participants enrolled in all of the three study Arms A, B, and C;   Hormone progesterone levels obtained from individual participants enrolled in all of the three study Arms A, B, and C
15 Recruiting Quick Start of Highly Effective Contraception
Conditions: IUD;   Contraceptive Implant;   Contraception;   Birth Control;   Emergency Contraception
Interventions: Drug: Copper T-380 IUD;   Drug: LNG IUD;   Device: Contraceptive implant Nexplanon;   Drug: Depo-Provera
Outcome Measures: Pregnancy rates in the first month of contraceptive use;   Contraceptive Continuation Rates
16 Recruiting Tamoxifen for the Treatment of Unfavorable Bleeding in Contraceptive Implant Users
Conditions: Irregular Vaginal Bleeding;   Frequent Vaginal Bleeding;   Contraceptive Implant
Interventions: Drug: Tamoxifen;   Drug: Placebo
Outcome Measures: Bleeding days;   Satisfaction;   Ovulation
17 Recruiting Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With an Oral Contraceptive
Conditions: Abnormal Uterine Bleeding, Unspecified;   Uterine Bleeding Heavy
Interventions: Drug: EE 30mcg/LNG 150mcg;   Drug: Placebo
Outcome Measures: Bleeding Improvement;   Adverse Events
18 Not yet recruiting Computerized Decision Aid
Conditions: Contraception;   Decision Making;   Satisfaction;   Evaluation
Intervention: Other: CDM Tool
Outcome Measures: Percent of women using IUD, Implanon and injectable contraception;   Average decisional conflict score;   Self-reported satisfaction with contraceptive counseling;   Self-reported continuation and satisfaction rate with contraceptive method
19 Recruiting Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
Condition: HIV Infections
Interventions: Drug: Current ARV medications;   Drug: Current TB medications;   Drug: Current hormonal contraceptive medications
Outcome Measures: Drug parameter: Area under the curve from 0 to 12 hours (AUC 0-12);   Drug parameter: Area under the curve from 0 to 24 hours (AUC 0-24);   Drug parameter: Maximum concentration (Cmax);   Drug parameter: Pre-dose concentration (Cdose);   Drug parameter: Minimum concentration (Cmin);   Drug parameter: Time after administration of drug when maximum plasma concentration is reached (Tmax);   Drug parameter: Clearance over systemic availability (Cl/F);   Drug parameter: Volume of distribution over systemic availability (V/F);   Drug parameter: Half-life (t1/2);   ARV concentrations in vaginal secretions;   ARV concentrations in plasma;   For contraceptives: plasma concentration;   Ratio of cord blood concentration to maternal blood concentration;   Ratio of unbound/total drug concentrations;   Rate of detection of study drugs in vaginal secretions;   Ratio of vaginal drug concentrations to simultaneous blood concentrations;   Rate of detection of HIV RNA/DNA in vaginal secretions and comparison to level in blood;   ARV exposure (as measured by area under the curve or other PK parameters) during pregnancy and postpartum according to genotype;   Adverse events of grade 3 or higher;   Infant neurological events of grade 1 or higher;   Adverse pregnancy outcome: preterm birth;   Adverse pregnancy outcome: low birth weight;   Adverse pregnancy outcome: fetal demise;   Adverse pregnancy outcome: congenital anomalies;   Infant HIV infection status
20 Recruiting In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products
Condition: HIV Prevention
Interventions: Drug: Tenofovir 1% gel;   Drug: Vaginal product
Outcome Measures: TFV concentrations in plasma and genital tissue and TFV-DP concentrations in genital tissue;   Vaginal product concentration in plasma;   Genitourinary adverse events (AEs)

These studies may lead to new treatments and are adding insight into Implanon etiology and treatment.

A major focus of Implanon research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Implanon